Full Press Release Details
Aurora Cannabis and EnWave Corporation
Enter Global Licensing Arrangements
Establish Intellectual
Property Partnership and $10 Million Strategic Equity Investment
EDMONTON and VANCOUVER, April 26, 2019 /CNW/
- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) and
EnWave Corporation (TSX-V:ENW) (FSE:E4U) ("EnWave") announced today that the companies have
entered into a royalty-bearing commercial license agreement (the "License"), providing Aurora with the exclusive rights
to EnWave's patented Radiant Energy Vacuum (REVTM) drying technology for the production of cannabis materials in the
European Union, excluding Portugal. Aurora has also secured exclusive license options for both Australia and South America,
excluding Peru, exercisable pursuant to minimum REV machine purchase order requirements. Additionally, Aurora has signed
a non-exclusive sub-license (the "Sub-License") to use REV technology in Canada.
The companies furthermore announce that Aurora
has placed a purchase order for two of EnWave's 120kW REVTM dehydration systems for its Aurora Sky and Aurora Sun facilities
in Canada, as well as the intention to purchase a third 120kW REVTM dehydration system for its Aurora Nordic facility
in Denmark within sixty days. The REVTM dehydration systems will be used to increase throughput of material for extraction
and use in derivative cannabis products. Aurora has also acquired a 10kW pilot-scale REV machine for product development,
protocol development and R&D.
Strategic Partnership Forged
EnWave's patented REV technology is
a rapid, low temperature, continuous drying method that maintains the optimal terpene profile, flavour, as well as other product
attributes during the drying process. The company's vacuum-microwave technology enables uniform drying with flexible moisture content,
unattainable with freeze drying or air drying. Aurora and EnWave have agreed to enter into an Intellectual Property Agreement (the
"IPA") with the intent to jointly-develop new innovations relating to REV technology that are applicable to the
cannabis industry. All intellectual property developed under the IPA will be owned by EnWave, but any realizable commercial value
will be shared on an undisclosed basis with Aurora. All other terms of the IPA are confidential.
Pursuant to the License, Aurora will share
an undisclosed percentage of the royalties generated through the sub-licensing of EnWave's patent portfolio to sub-licensees in
the jurisdictions where the Company holds the exclusive rights to REV technology. EnWave and Aurora will jointly benefit
through economic alignment by working together to propagate the global cannabis industry with REV machinery.
Strategic Equity Investment
To further cement the economic alignment between
the companies, Aurora has made a $10 million strategic equity investment in EnWave. Pursuant to the terms of a share purchase agreement
between the parties dated April 25, 2019, Aurora has purchased 5,302,227 common shares in the capital of EnWave (the "EnWave
Shares") at a deemed price of $1.886 per share, based on the volume weighted average trading price ("VWAP") for
EnWave's shares on the TSX Venture Exchange (the "TSXV") for the five (5) consecutive trading days to and including April
22, 2019. As consideration for the EnWave Shares, Aurora issued to EnWave 840,576 common shares in the capital of Aurora (the "Aurora
Shares") at a deemed price of $11.8966 per share, based on the VWAP for Aurora's shares on the Toronto Stock Exchange (the
"TSX") for the five (5) consecutive trading days to and including April 22, 2019. The EnWave Shares represent approximately
4.91% of the issued and outstanding common shares of EnWave on a non-diluted basis.
EnWave received conditional approval for the
transaction from the TSXV on April 12, 2019. The TSX and NYSE have conditionally approved the listing of the Aurora Shares on such
exchanges. Each of the EnWave Shares and the Aurora Shares will be subject to a hold period of four months and one day from the
date of issuance pursuant to applicable securities laws.
Management Commentary
"EnWave's technology offers very significant
benefits that further improve the economic returns on our Sky Class facilities," said Terry Booth, CEO of Aurora. "The
technology provides us with industrial-scale flow-through, reducing working capital requirements, accelerating time to market from
harvest, as well as increasing our ability to produce bulk-sale cannabis for extraction and use in derivative products. Our ownership
interest in EnWave and the exclusive license arrangement in many of our current and target markets creates the potential to generate
additional financial synergies."
Brent Charleton, CEO of EnWave, stated, "EnWave's
growth continues to accelerate, and we are delighted to have Aurora as an investor, industry partner and technology collaborator
to further the enhancement and propagation of EnWave's REV drying technology. This partnership brings together two innovation
leaders in the cannabis industry, and we look forward to working closely with the team at Aurora to deliver further value to our
CapEx and Working Capital Savings
Inclusion of EnWave's REV technology
in the design of the Aurora Sun and Aurora Nordic facilities will result in significant CapEx savings on drying space (smaller
footprint) and related HVAC investments. Inclusion of the technology in the existing Aurora Sky facility will also free up space,
which can be repurposed to increase the economic output of the facility.
EnWave's REV technology furthermore
reduces drying time from 5-7 days to less than one hour, resulting in significant working capital savings and speed to market of
product. The technology has certain additional benefits, including the support of industrial scale flow-though, accelerating the
ability for large-scale processing of cannabis and CBD-rich biomass into intermediate or finished product.
License Agreement Details
Aurora will have an exclusive license, with
sub-licensing rights to EnWave's REV technology in the European Union (excluding Portugal) and exclusive options to secure
the same rights in South America (excluding Peru) and Australia. Aurora will pay EnWave a royalty on all cannabis products processed
using the REV machinery. Aurora will receive an undisclosed share of royalties derived from any cannabis product dried with
REV technology by sub-licensees in jurisdictions where it holds the exclusive license. Aurora will have a non-exclusive
sub-license to the EnWave technology in Canada and will pay EnWave a royalty on cannabis product processed in Canada using REV
Headquartered in Edmonton, Alberta, Canada
with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora
is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across
every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis
and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are
designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards. EU GMP certification has been granted to Aurora's first production
facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora
In addition to the Company's rapid organic
growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf,
CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,
CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, and Chemi Pharmaceutical -
Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in
and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco
Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE:
CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc.
(TSX: CLIQ) and High Tide Inc. (CSE: HITI).
Aurora's Common Shares trade on the TSX and
NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit
our investor website, investor.auroramj.com
EnWave Corporation, a Vancouver-based advanced
technology company, has developed Radiant Energy Vacuum ("REV ") - an innovative, proprietary method for
the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating
cannabis through the use of REV technology, shortening the time from harvest to marketable cannabis products.